Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer

#Ki67 after #anthracycline-based #NeoadjuvantChemotherapy independently predict pathological complete response and overall response in early #BreastCancer, supporting dynamic Ki-67 change as a #biomarker to guide #PostSurgical treatment decisions.
Read: doi.org/10.1007/s115...

We performed #RNAseq and #TIL assessment in serial biopsies from the NA-PHER2 trial. High #immune #infiltration and low #ER signalling at baseline correlated with #pCR, while #TP53 mutations associated with high Day14 #Ki67